JP2024527362A5 - - Google Patents
Info
- Publication number
- JP2024527362A5 JP2024527362A5 JP2024500476A JP2024500476A JP2024527362A5 JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5 JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024500476 A JP2024500476 A JP 2024500476A JP 2024527362 A5 JP2024527362 A5 JP 2024527362A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- sequence
- optionally
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220108P | 2021-07-09 | 2021-07-09 | |
| US63/220,108 | 2021-07-09 | ||
| PCT/US2022/073529 WO2023283615A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527362A JP2024527362A (ja) | 2024-07-24 |
| JP2024527362A5 true JP2024527362A5 (enExample) | 2025-07-17 |
Family
ID=84802089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500476A Pending JP2024527362A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318177A1 (enExample) |
| EP (1) | EP4366783A4 (enExample) |
| JP (1) | JP2024527362A (enExample) |
| KR (1) | KR20240035826A (enExample) |
| CN (1) | CN118591391A (enExample) |
| AU (1) | AU2022306692A1 (enExample) |
| CA (1) | CA3226307A1 (enExample) |
| IL (1) | IL309935A (enExample) |
| MX (1) | MX2024000493A (enExample) |
| WO (1) | WO2023283615A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| ES2639852T3 (es) * | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| AU2017364106A1 (en) * | 2016-11-28 | 2019-06-20 | The Board Of Regents Of The University Of Texas System | Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| EP4023673A4 (en) * | 2019-10-10 | 2023-03-15 | Suzhou Qin Pharmaceuticals Co., Ltd. | ANTI-BCMA HUMANIZED MONOCLONAL ANTIBODY WITH HUMAN-MONKEY CROSS-REACTIVITY |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 JP JP2024500476A patent/JP2024527362A/ja active Pending
- 2022-07-08 CA CA3226307A patent/CA3226307A1/en active Pending
- 2022-07-08 WO PCT/US2022/073529 patent/WO2023283615A1/en not_active Ceased
- 2022-07-08 KR KR1020247004340A patent/KR20240035826A/ko active Pending
- 2022-07-08 MX MX2024000493A patent/MX2024000493A/es unknown
- 2022-07-08 US US18/577,378 patent/US20240318177A1/en active Pending
- 2022-07-08 EP EP22838587.8A patent/EP4366783A4/en active Pending
- 2022-07-08 IL IL309935A patent/IL309935A/en unknown
- 2022-07-08 AU AU2022306692A patent/AU2022306692A1/en active Pending
- 2022-07-08 CN CN202280060812.8A patent/CN118591391A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527362A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| KR20240035825A (ko) | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 및 제제 | |
| JP2023509793A5 (enExample) | ||
| JP2024540199A5 (enExample) | ||
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2024534488A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2025512468A5 (enExample) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 |